Apply Give

Other ways to search: Events Calendar | UTHSC

Daxor Corporation Presents New Data Validating the Benefit of the BVA-200 Blood Test for Heart

Written by Communications and Marketing

|

Daxor Corporation, the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 blood test in optimizing individualized therapy for heart failure patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2021 – which brought together the world’s leading experts in heart failure from September 10-13, 2021, in Denver, CO. “Combined use of blood volume analysis and ultrafiltration should improve outcomes in hospitalized diuretic-resistant or renal insufficient patients,” stated John L. Jefferies, M.D., MPH, FACC, FAHA, FAAP, FHFS, University of Tennessee Health Science Center, Memphis, TN, and lead data investigator.

Top Publishers